Breakthrough Nerve-Sensing Technology
Detecting nerve signals could help treat everything from high blood pressure to pain. Our revolutionary nerve-sensing technology has shown to be thousands of times more sensitive than what’s available today.
Our most recent funding round has closed. Thank you to everyone who invested.
Investment Highlights
$100B
Worldwide Market Opportunity
15
Distinct Wholly-Owned Patent Families (Includes 100+ Patents)
$900M
Individual Acquisitions of Electrophysiology Companies Before Receiving FDA or EMA Approval
NASDAQ Here We Come. Meet AMIX.
We’ve filed our Form 1-A offering statement which has been qualified and have applied to be listed on the NASDAQ under the symbol "AMIX" following this funding round.
Sign up to receive exclusive investor updates
The Nervous System Is the Key to Faster, Safer, and More Effective Treatments
The nervous system is responsible for some of the body’s most important functions. But today’s technology is too limited to see into the nervous system with sufficient precision. Our team is uniquely capable of solving this problem. Our leadership has a track record of building medical companies and technologies that have created billions in value for brands like AbbVie and Boston Scientific.
We Are Developing the Equivalent of a GPS for the Nervous System
Clearer visibility into the nervous system can open doors to new treatments and diagnostic techniques. Our technology boasts thousands of times more sensitivity than current tools, potentially allowing us to pinpoint and treat nerves in problem areas, opening the doors for new treatments across a wide range of disorders.
Potential Applications
Hypertension
Pain Management
CRPS
Pulmonary Disorders
Urinary Tract Disorders
Digestive Disorders
Organ-Related Disorders
Cardiology
Our Breakthrough Technology Fits on the Head of a Pin
Using the same electronics form factor found in the Apple Watch, we've reduced the equivalent of today’s “suitcase” sized equipment for detecting and analyzing electrical signals within the body down to a 1 x 2-millimeter microchip. This makes the sensing technology being developed in our proposed device small enough to travel into the cardiovascular system, which would give us access to the nerves throughout the body with a potential sensitivity never before possible.
Custom
Antenna Array
Our state-of-the-art custom antennae array detects, maps, displays and modulates the problem area accurately and safely.
Guidewire & Catheter Bodies
Small enough to reach any organ. Proprietary, low-cost production.
Proprietary Chipset
Equipped with embedded microelectronics, our patented chipset enables robust nerve signal processing at the source.
Download the Autonomix Investor Deck
Unlocking the Power of the Nervous System Is a $100B Opportunity
We’re starting out by targeting pancreatic cancer pain – and the pancreatic cancer treatment market is estimated to be $2.2B per year. Pancreatic cancer causes severe pain and current available pain management therapies have limited efficacy and can include a high risk of serious complications. While we see this as a critical unmet medical need, we also believe it has the potential to be a relatively quick and cost-effective proof of concept that will open the door to over $100B market opportunities targeting the broader pain management market, hypertension, cardiology and more.
Over 100 Patents (Issued + Pending) Protect Our Innovations
We have 100+ patents issued and pending across 15 wholly-owned patent families. Not only does this show the scale of our innovation, but you can invest knowing our patents create a significant barrier to entry for other players.
Similar Companies Have Received Investment Or Been Acquired in Deals Worth $900M+
This is a great opportunity for investors to own shares in a company with a large intellectual property portfolio with a range of potential use cases. We’re in the same industry as Elon Musk’s Neuralink, where companies like Medtronic and Boston Scientific have spent as much as $900M+ on individual acquisitions. We’ve already filed to list on the Nasdaq once our funding round ends.
Download the Autonomix Investor Deck
Not Ready To Invest?
Fill out the form below to receive more info from Autonomix
Roadmap to 2026
Sensing Technology Development
Sensing Proof in Animals
IP Portfolio Built
Sensing Safety in Animals
Sensing Catheter Development
Catheter Development for Ablation System
Feasibility Testing in Animals
POC-First-in-Human Clinical Trial - Pancreatic Cancer Pain
Sensing Technology Development
Sensing Safety in Animals
Animal Safety Testing
Human Clinical Ablation Device Development
Combined Sensing / Ablation Clinical Trial
Industry exıt wındow
Ablation System and Catheter Ready
for Human Pivotal
Combined Sensing / Ablation Clinical Trial
De Novo Submission
Transfer to Manufacturing
FDA Clearance
Latest Updates
50+ Years of Experience
Med device exit to AbbVie(Nasdaq: SOLY; $0.6 billion 12/21
4 successful IPOs
~$1 Billion development and growth stage financing
3 successful IPOs
Med device exit to AbbVie
Deep life science / med tech experience
Inventor of Watchman ($1 Billion revs; sold to Boston Scientific)
Mayo Clinic
Director Minneapolis Heart Institute
International Cardiologist
Mechanical engineer/medical device expert
Commercialization of wearable and interventional diagnostic medical technologies
SEC reporting background
Med tech background
FAQs
$5.00
$750
Common stock
Up to $20M
Pre-money valuation is approximately $70M
The company has applied to list on NASDAQ and has reserved the symbol “AMIX” and if approved will trade immediately following the closing of the offering on NASDAQ.*
Autonomix is developing potentially revolutionary, class-leading technology that could solve some of the biggest problems in medicine, including diagnosing and treating nearly anything related to the nervous system. In total, we believe this could be a $100B market opportunity.
Our nerve-sensing technology places Autonomix at the core of an estimated $100B market opportunity. We intend to introduce our sensing and ablation technologies into this space, selling catheters to treat various conditions to the hospitals and clinics that provide treatments to patients. We anticipate that our procedures will be covered by insurance for patients.
Based on animal studies we have completed, our device is thousands of times more sensitive than what current companies doing similar work are doing. They are targeting a space with limited or inferior options for physicians to provide their patients today.
The proceeds will be used to further develop our product and perform clinical and preclinical testing to support our regulatory filings that will be necessary to clear our product for commercial use. Additionally, the proceeds will be used for working capital.
Investing in startups is risky and there is no guarantee you will get a return on your investment. However, an exit opens up the opportunity where you could convert your shares into cash or a more liquid asset. Exits include going public or getting acquired by a larger company. If the value of our company grows, then you have a higher potential of making a profit on your investment during one of these exits. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
The funds raised in this round are expected to provide one year of cash runway for the company.
The plan is to build a successful, valuable company. Exit opportunities like an acquisition could follow in due course if we are able to demonstrate the value our technology brings to the marketplace through clinical results.
We are initially focused on treating pancreatic cancer pain as it is an area with significant unmet needs for patients.
Your shares will be held at the transfer agent on closing in your name.
Transfer agents maintain a record of ownership, including contact information, of an issuer’s registered stockholders. After the Common Stock is listed on NASDAQ, you will be able to deposit any shares you purchased with a broker. Until you deposit your shares in a brokerage account, the transfer agent will maintain the record of your ownership. Once you deposit your shares with a broker, the broker will maintain that record.
Your shares will be freely tradeable through the broker of your choice once the company is listed on NASDAQ. The transfer agent is Equity Stock Transfer “EST” – all investors will receive a Welcome Letter directly from EST with information on how to access and manage their accounts.
No, costs are the same, regardless of how you invest.
The company is a Delaware corporation.
All of Autonomix’s regulatory filings, including financial reports, can be found here: https://www.sec.gov/edgar/browse/?CIK=1617867
ABOUT AUTONOMIX
Autonomix has made a first-in-class technology platform that includes a catheter-based microchip-enabled sensing array that can detect and differentiate neural signals with an extremely high degree of sensitivity from within the vascular structure. We believe this will enable a method of targeting, treating, and confirming the treatment of diseases involving the nervous system throughout the body that is not currently available and may be capable of filling a wide range of unmet medical needs. At Autonomix, we not only own the exclusive patent rights to this approach, but we’ve actually proven that it works in animal models, and we are now preparing to demonstrate it in human clinical trials.
The corporate headquarters is in the Woodlands, TX but our development facilities are located in Warminster, PA.
5 full and part-time employees supported by 10-15 dedicated consultants.
Autonomix will focus on securing clearance to sell its products first in the United States and intends to expand internationally after successfully launching domestically. Successful international expansion will require the company to secure additional regulatory clearances in those jurisdictions.
15 patent families (representing various inventions relating to different aspects of technology) comprising over 100 patents either issued or pending.
If approved, we believe we will offer a better alternative to the traditional “treat and pray” approach. Unlike random treatments that can cause collateral damage, our technology precisely targets the problematic nerves, minimizing risks and side effects.
We believe our technology can potentially treat any disease related to the peripheral nervous system. However, our initial focus is on helping pancreatic cancer patients suffering from severe pain that cannot be adequately managed with existing methods.
Autonomix’s technology holds the potential to usher in a new era of personalized medicine by allowing doctors to tailor treatments to individual neural profiles. This precision can lead to more effective interventions, fewer side effects, and improved patient experiences across a spectrum of diseases.
The transvascular approach is groundbreaking because it enables doctors to access nearly any nerve within the body through commonplace catheters. This approach opens new avenues for minimally invasive diagnosis and targeted treatment of conditions involving the peripheral nervous system, offering patients safer and more effective solutions.
Autonomix achieves high sensitivity by using a catheter-based sensing system equipped with a proprietary microchip and a unique antenna sensing array. This combination converts analog signals from the body into digital data with unparalleled sensitivity, capable of detecting signals as low as 0.5 microvolts.
If approved, this approach will provide a safer and more effective alternative by targeting the specific nerves responsible for pain or disease. This minimizes the reliance on painkillers and opioids, which often come with side effects and diminishing effectiveness over time. The goal is to improve patient outcomes and quality of life by offering precise and lasting relief.